moderately obese subjects in our study was identical to that reported in a recent meta-analysis on long-term pharmacotherapy for obesity. 2 In response to Ornish's letter: the low-carbohydrate diet was based on Atkins's book, although we encouraged the study participants to consume a variety of protein and fat sources to maintain successful long-term adherence. We specifically reported on retention in detail and noted that adherence was higher in this trial than in any other trial of a similar length that we know of. The setting and methods we used to maximize adherence rates permitted a robust test of the three dietary strategies, as assessed by weight loss and established measurements of lipids, glycemic control, and hepatic and inflammatory biomarkers. As noted by Manzoni and colleagues, we did not assess cost-effectiveness. However, we believe that cost-effective interventions can be implemented in the workplace, with the use of group meetings and by working with food-service providers.
Several readers have informed us that our online Supplementary Appendix was incomplete. We have updated the appendix to provide more complete information. 
Tibolone in Older Postmenopausal Women
To the Editor: In a randomized study of the effect of tibolone on fracture rates among postmenopausal women between the ages of 60 and 85 years, Cummings et al. (Aug. 14 issue) 1 report that tibolone significantly reduced the risk of invasive breast cancer. The authors also report that this finding contradicted the results of the observational Million Women Study, which showed that the use of tibolone for up to 5 years was associated with an increased risk of breast cancer. 2 In analyses combining clinical-trial and observational-study cohorts, the Women's Health Initiative (WHI) showed that a decreased risk of breast cancer was associated with estrogen therapy only if estrogen was given several years after menopause and not when it was begun soon thereafter. 3 Since women in nontrial settings usually begin such hormonal therapy shortly after the onset of menopause, the gap time after menopause provides a potential effect modifier, suggesting caution in extrapolating findings to women closer to menopause. In the WHI randomized trial, estrogen plus progestin increased the risk of breast cancer that was diagnosed at an advanced stage, suggesting diagnostic delay with fewer cancers in the hormone group through the first 3 years of follow-up. 4 The current tibolone trial was reported after a median of 34 months and without information on tumor stage. Although tibolone does not increase breast density, as does combined hormone therapy, 5 could diagnostic delay account for some of the breast-cancer findings? To the Editor: With respect to the study by Cummings et al, we raise two issues: First, among the risk factors for stroke, the authors did not include the presence of high triglyceride levels and low levels of high-density lipoprotein (HDL) cholesterol, which have been shown to be related to ischemic cerebrovascular events. 1,2 Were these values similar in the two study groups at baseline? Were they modified by the administration of tibolone? Second, regarding gynecologic outcomes, patients who were treated with tibolone had a significantly higher incidence of mild cervical dysplasia on cytologic analysis than did those receiving placebo (7.6% vs. 3.2%, P = 0.009), but there were no differences between the groups in the incidence of moderate-to-severe dysplasia. Several studies have noted a synergistic role of sex hormones with human papillomavirus (HPV) infection in facilitating cervical carcinogenesis by inducing squamous metaplasia and by modifying the local immune microenvironment. 3, 4 This carcinogenic process requires several years. In the study by Cummings et al., the median duration of treatment was 34 months. We wonder whether in this period of time the possible HPV hyperactivation induced by tibolone could have caused mild dysplasia, whereas higher-grade dysplasia would have required a longer exposure. 
